登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:002880 证券简称:卫光生物 公告编号:2025-008 深圳市卫光生物制品股份有限公司 关于2024年度日常关联交易执行情况及 预计2025年度日常关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、日常关联交易基本情况 （一）日常关联交易概述 深圳市卫光生物制品股份有限公司（以下简称公司）于2025年4月21日召开第三届董事会第三十二次会 议、第三届监事会第二十五次会议审议通过了《关于2024年度日常关联交易执行情况及预计2025年度日 常关联交易的议案》。 公司及子公司基于实际经营需要，预计2025年与关联方武汉生物制品研究所有限责任公司发生日常关联 交易的金额为100万元，公司2024年实际发生的日常关联交易金额为2.88万元。 根据《深圳证券交易所股票上市规则》《公司章程》等的相关规定，本事项无需提交公司股东大会审 议。 （二）2024年度日常关联交易执行情况 ■ （三）预计2025年度日常关联交易情况 ■ 二、关联方及关联关系 公司名称：武汉生物制品研究所有限责任公司 ...

华恒生物公告，2024年度实现营业总收入21.78亿元，同比增加12.37%；归属于母公司所有者的净利润 1.9亿元，同比减少57.80%。公司拟向全体股东每10股派发现金红利2.5元(含税)，合计拟派发现金红利 6230.68万元(含税)，占公司2024年度合并报表归属于上市公司股东净利润的比例为32.88%。 ...

卫光生物（002880）公告，2024年营业收入12.03亿元，同比增长14.75%。归属于上市公司股东的净利 润2.54亿元，同比增长15.95%。基本每股收益1.12元/股，同比增长15.94%。公司拟向全体股东每10股派 发现金红利2元(含税)，送红股0股(含税)，不以公积金转增股本。 ...

卫光生物（002880）公告，2025年第一季度营业收入2.25亿元，同比下降0.57%。净利润4376.82万元， 同比下降6.54%。 ...

特宝生物公告，2025年第一季度营收为6.73亿元，同比增长23.48%；净利润为1.82亿元，同比增长 41.40%。 ...

Investment Rating - The investment rating for the company is upgraded to "Buy" [1] Core Views - The company experienced a steady growth in its conventional business, but increased investments have put pressure on profit margins [4] - In 2024, the company achieved a revenue of 614 million yuan, a year-on-year decrease of 5.06%, while the net profit attributable to the parent company was 122 million yuan, down 53.13% year-on-year [4] - The conventional business generated a revenue of 533 million yuan in 2024, reflecting a year-on-year growth of 10.54% [4] - The company has adjusted its profit forecasts for 2025-2026 and added a new forecast for 2027, expecting net profits of 156 million, 183 million, and 209 million yuan respectively [4] Financial Summary - In 2024, the company’s revenue from the recombinant protein business was 273 million yuan, up 6.87% year-on-year, while the antibody business revenue fell to 106 million yuan, down 41.20% [5] - The CRO service business generated a revenue of 169 million yuan, marking a year-on-year increase of 9.40% [5] - The company’s overseas revenue reached 354 million yuan in 2024, accounting for 57.74% of total revenue [6] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.28, 1.50, and 1.72 yuan respectively, with corresponding P/E ratios of 47.4, 40.4, and 35.3 times [4][8]

Investment Rating - The investment rating for the company is upgraded to "Buy" [1] Core Views - The company experienced a steady growth in its conventional business, but increased investments have put pressure on profit margins [4] - In 2024, the company achieved a revenue of 614 million yuan, a year-on-year decrease of 5.06%, while the net profit attributable to the parent company was 122 million yuan, down 53.13% year-on-year [4] - The conventional business generated a revenue of 533 million yuan in 2024, reflecting a year-on-year growth of 10.54% [4] - The company has adjusted its profit forecasts for 2025-2026 and added a forecast for 2027, expecting net profits of 156 million yuan, 183 million yuan, and 209 million yuan respectively [4] Financial Summary - In 2024, the company’s revenue from the recombinant protein business was 273 million yuan, a year-on-year increase of 6.87% [5] - The antibody business saw a revenue decline to 106 million yuan, down 41.20% year-on-year [5] - The CRO service business generated 169 million yuan in revenue, marking a year-on-year growth of 9.40% [5] - The company’s overseas revenue reached 354 million yuan in 2024, accounting for 57.74% of total revenue [6] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.28 yuan, 1.50 yuan, and 1.72 yuan respectively [4] Valuation Metrics - The current price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 47.4, 40.4, and 35.3 respectively [8] - The gross margin for 2024 is reported at 73.3%, with a net margin of 19.9% [8] - The return on equity (ROE) for 2024 is 2.1% [8]

Group 1: Baike Biotechnology - Baike Biotechnology's performance in Q1 2024 and Q1 2025 is expected to decline significantly, with decreases of 32.64% and 39.96% respectively, primarily due to the impact on shingles vaccine sales [1] - The company plans to enhance market awareness of the shingles vaccine, maintain its position in the chickenpox vaccine market, and expand into international markets [1] - Several R&D projects have made progress, including liquid nasal spray flu vaccines and rabies monoclonal antibodies, with an anticipated increase in R&D and sales expense ratios in 2025, followed by a gradual decrease [1] Group 2: Qinchuan Machine Tool - Qinchuan Machine Tool's operating performance in 2024 shows a significant increase in high-tech product exports, with machine tool export revenue growing by 35% year-on-year, covering regions such as Europe, South America, East Asia, and Africa [2] - The company has developed manufacturing capabilities for components suitable for humanoid robots and has initiated extensive R&D efforts, leveraging 60 years of technological advantage [2] - Qinchuan's industrial robot joint reducers feature five major series, over 40 specifications, and 140 different speed ratios, with an annual production capacity of 60,000 to 90,000 sets, serving clients like Guoshu Turing and Estun [2] - During the 14th Five-Year Plan period, the company will focus on its core machine tool business, promoting high-end, intelligent, and green development to enhance core competitiveness and aims to become a global leader in machine tool manufacturing and precision transmission solutions [2] - Walker Gear, in the new energy sector, emphasizes high-precision gears with advantages in mature processes, low costs, and good after-sales quality [2] - Qinchuan's five-axis machining center products have four major series and over 20 models, with comprehensive performance indicators leading domestically and significantly increased market penetration [2]

调研纪要：蒙娜丽莎在2024年面对贸易环境变化、房地产调整等多重挑战，采取了一系列应对措施。贸 易壁垒导致建陶行业出口量、额、价齐跌，企业转向新兴市场；公司营业收入下降，销售量同比下降 16.34%，销售结构变化影响价格；营业成本下降20.72%，主要由直接材料和燃料动力成本下降引起； 降本增效措施效果显现，但未来空间有限；公司经营活动现金流良好，将继续通过现金分红回报投资 者；对部分房地产客户应收账款进行信用减值损失单项计提，将持续关注并评估；展望2025年，行业面 临需求减弱等挑战，但城镇化推进、存量房改造等带来新机遇。 机构简介： 深圳正圆投资2015年成立于深圳前海自贸区，并于当年获得私募证券投资基金牌照。正圆拥有专业的投 研团队，丰富的投资经验，完善的风险管理制度。 立足于中国经济结构转型升级，服务于中国实体经 济发展。依赖团队专业的投研能力，致力于成为社会资本与优质产业之间的纽带，通过将客户资产配置 于符合发展趋势的优质公司，实现客户资产的保值增值。 以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。 根据市场公开信息及4月2 ...

Group 1: Ganyuan Food - Ganyuan Food plans to conduct in-depth research in the Southeast Asian market starting in Q4 2024, with an accelerated product export strategy in 2025 [1] - The company is addressing raw material fluctuations through advance reserves, supply chain alternatives, and increasing direct procurement [1] - The growth in accounts receivable is primarily due to the staggered impact of the Spring Festival, leading to increased receivables during peak sales periods [1] - The growth of mixed nuts and bean snacks is attributed to bulk snack channels and overseas markets [1] - A significant promotional effort in Q1 2024 resulted in lower e-commerce gross margins, but gross margins are expected to rise year-on-year in Q1 2025 [1] - Sales expenses in Q1 2025 are expected to increase due to the initiation of the Southeast Asia export strategy, including market research, product design, sales personnel costs, and new celebrity endorsement fees [1] Group 2: Lepu Medical - Lepu Medical is optimistic about future profit growth from structural heart, dermatology, and neuro-regulation businesses [2] - The company has set profit margin assessments for each business segment and is controlling costs to maintain healthy cash flow [2] - The trend of centralized procurement may moderate, with significant regional differences across provinces [2] - The impact of US-China tariffs on the company is limited, and the domestic substitution process for some products may accelerate [2] - The promotion of new cardiovascular interventional products is progressing smoothly, with a sales target for coronary interventional business set for a 10% year-on-year increase [2] - The non-invasive blood glucose meter is undergoing further testing, and the candidate drug MWN101 has completed Phase II clinical trials [2] - The brain-computer interface business is in the incubation stage, and the market share of coronary stents has not met expectations, prompting increased focus on this area [2] - The AI business will increasingly integrate with hardware devices, and opportunities exist for DSA product promotion amid US-China trade tensions [2] - The company is placing greater emphasis on the neuro-regulation pipeline due to competition in the cardiac electrophysiology sector [2] - The TAVR product aims to enhance its popularity through reasonable pricing [2] Group 3: Baike Biotech - Baike Biotech experienced significant declines in performance for 2024 and Q1 2025, with decreases of 32.64% and 39.96% respectively, primarily due to the impact on shingles vaccine sales [3] - The company plans to enhance market awareness of the shingles vaccine through various methods while maintaining its position in the chickenpox vaccine market and expanding into international markets [3] - In terms of R&D, multiple projects have made progress, including liquid nasal spray flu vaccines and rabies monoclonal antibodies [3] - The company anticipates an increase in R&D investment and sales expense ratios in 2025, followed by a gradual decline [3]